(SeaPRwire) –   By: Logan Pierce

Pfizer’s stock edged up 1.36% to $26.04 as it ramps up in obesity, cancer, and vaccines. But a looming patent cliff could derail its long-term growth.

At the American Diabetes Association conference, Pfizer presented Phase 2b data on berobenatide, a once-monthly GLP-1 injection. In trials, it showed about 15% body weight loss. This could be the first monthly obesity therapy, competing with weekly options like Wegovy and Zepbound. Pfizer plans over 20 trials in 2026 for obesity and metabolic conditions, including 10 Phase 3 studies for berobenatide, and aims to expand into China and Japan.

Pfizer is also active in cancer and vaccines. It’s launched oncology trials combining an experimental antibody drug with others, and started recruiting for a Phase 3 trial of a new pneumococcal conjugate vaccine for infants. A $10.5 billion partnership with Innovent Biologics covers 12 cancer drugs, with just $650 million upfront.

However, Pfizer faces financial challenges. Revenue last year was $62.6 billion, down from $100 billion in 2022. Three top drugs face patent expiry next year, worth over $20 billion in 2025 revenue. Long-term debt is $60.5 billion, costing $670 million in interest quarterly. The forward dividend yield is 6.7%, reflecting both income and risk.

Author bio: Logan Pierce, independent business writer covering pharma and biotech trends.